NCI-BL1607 [BL1607, BL9, NCI-BL9] (ATCC® CRL-5953)

Organism: Homo sapiens, human  /  Cell Type: B lymphoblast; Epstein-Barr virus (EBV) transforme  /  Disease: Cancer

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Cell Type B lymphoblast; Epstein-Barr virus (EBV) transforme
Product Format frozen
Morphology lymphoblast
Biosafety Level 2
Disease Cancer
Age 54 years
Gender male
Ethnicity White
Derivation
NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer.
Clinical Data
NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer.
The patient was a smoker.
male
White
54 years
Comments
NCI-BL1607 is a B lymphoblastoid cell line initiated by Epstein-Barr virus (EBV) transformation of peripheral blood lymphocytes obtained from a lymph node metastasis from a patient with primary small cell lung cancer.
The patient was a smoker.
20 pack years.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(6) viable cells/ml.
Maintain cell density between 1 X 10(6) and 3 X 10(6) viable cells/ml.
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X,Y
CSF1PO: 10
D13S317: 9,12
D16S539: 11,13
D5S818: 11,12
D7S820: 8,12
THO1: 9.3
TPOX: 8,11
vWA: 17
Name of Depositor AF Gazdar, JD Minna
References

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

References

NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.